The biosynthetic potential of myxobacteria and their impact in drug discovery

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 2, 2009, Pages 220-230

  Wenzel, S C ^a   Muller R ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Biosynthetic potential; Myxobacteria; Myxococcus; Natural products; Non ribosomal peptide; Polyketide; Sorangium

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALTHIOMYCIN; ARGYRIN A; CAROTENOID; CERAMIDE; CEREBROSIDE; CHLOROTONIL A; CHONDRAMIDE; CORALLOPYRONIN; CRUENTAREN A; DISORAZOL; EPOTHILONE DERIVATIVE; LEUPYRRIN; MIURAENAMIDE A; MYXOPYRONIN; PEDEIN A; PEPTIDE SYNTHASE; PHOXALONE; POLYKETIDE SYNTHASE; PYRROLNITRIN; RIPOSTATIN; RNA POLYMERASE; SAFRAMYCIN; SORANGIADENOSINE; SORAPHINOL C; STEROID; THUGGACIN; TUBULYSIN; TUBULYSIN D; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BACTERIAL GENE; BACTERIAL GENOME; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; CELL FUNCTION; CYTOSKELETON; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENETIC ANALYSIS; METABOLITE; MICROTUBULE; MYXOCOCCALES; NONHUMAN; REVIEW; STEREOCHEMISTRY; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; GENE EXPRESSION REGULATION, BACTERIAL; GENE REGULATORY NETWORKS; HUMANS; MYXOCOCCALES; PEPTIDE SYNTHASES; POLYKETIDE SYNTHASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 62149106396     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Whitworth D (Ed): Myxobacteria: Multicellularity and Differentiation. ASM Press, Washington DC, USA (2007). • Provides an overview on the biology of myxobacteria, and also contains a chapter focusing on the ability of this bacteria to produce secondary metabolites (see also reference [3]).
2. Reichenbach H, Höfle G: Myxobacteria as producers of secondary metabolites. In: Drug Discovery from Nature. Grabley S, Thiericke R (Eds), Springer-Verlag Berlin Heidelberg, Germany (1999):149-179.
3. Bode HB, Müller R: Secondary metabolism in myxobacteria. In: Myxobacteria: Multicellularity and Differentiation. Whitworth D (Ed), ASM Press, Washington DC, USA (2007):259-282.
4. Gerth K, Pradella S, Perlova O, Beyer S, Müller R: Myxobacteria: Proficient producers of novel natural products with various biological activities - past and future biotechnological aspects with the focus on the genus Sorangium. J Biotechnol (2003) 106(2-3):233- 253.
5. Reichenbach H: Myxobacteria, producers of novel bioactive substances. J Ind Microbiol Biotechnol (2001) 27(3):149-156.
6. Eggert U, Diestel R, Sasse F, Jansen R, Kunze B, Kalesse M: Chondramide C: Synthesis, configurational assignment, and structure-activity relationship studies. Angew Chem Int Ed (2008) 47(34):6478- 6482.
7. Waldmann H, Hu TS, Renner S, Menninger S, Tannert R, Oda T, Arndt HD: Total synthesis of chondramide C and its binding mode to F-actin. Angew Chem Int Ed Engl (2008) 47(34):6473-6477.
8. Mulzer JH (Ed): The Epothilones - An Outstanding Family of Anti-Tumour Agents: From Soil to the Clinic. Springer-Verlag GmbH, Vienna, Austria (2009). •• Comprehensively reviews the discovery of epothilones and their development as cancer drugs. Epothilone is the first (and so far only) myxobacterial metabolite used in the clinic.
9. Reichenbach H, Höfle G: Discovery and development of the epothilones - a novel class of antineoplastic drugs. Drugs R&D (2008) 9(1):1-10.
10. Balasubramanian R, Raghavan B, Steele JC, Sackett DL, Fecik RA: Tubulysin analogs incorporating desmethyl and dimethyl tubuphenylalanine derivatives. Bioorg Med Chem Lett (2008) 18(9):2996-2999.
11. Patterson AW, Peltier HM, Sasse F, Ellman JA: Design, synthesis, and biological properties of highly potent tubulysin D analogues. Chem Eur J (2007) 13:9534-9541.
12. Raghavan B, Balasubramanian R, Steele JC, Sackett DL, Fecik RA: Cytotoxic simplified tubulysin analogues. J Med Chem (2008) 51(6):1530-1533.
13. Wang ZY, McPherson PA, Raccor BS, Balachandran R, Zhu GY, Day BW, Vogt A, Wipf P: Structure-activity and high-content imaging analyses of novel tubulysins. Chem Biol Drug Des (2007) 70(2):75-86.
14. Patterson AW, Peltier HM, Ellman JA: Expedient synthesis of N-methyl tubulysin analogues with high cytotoxicity. J Org Chem (2008) 73:4362-4369.
15. kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell (2008) 14(1):23-35. • Argyrin A is identified as a potential antitumor drug with a mode of action as a proteasome inhibitor.
16. Kunze B, Sasse F, Wieczorek H, Huss M: Cruentaren A, a highly cytotoxic benzolactone from myxobacteria is a novel selective inhibitor of mitochondrial F-1-ATPases. FEBS Lett (2007) 581:3523-3527.
17. Chakraborty TK, Chattopadhyay AK: Total synthesis of cruentaren B. J Org Chem (2008) 73:3578-3581.
18. Vintonyak VV, Maier ME: Total synthesis of cruentaren A. Angew Chem Int Ed Engl (2007) 46(27):5209-5211.
19. Fürstner A, Bindl M, Jean L: Concise total synthesis of cruentaren A. Angew Chem Int Ed Engl (2007) 46(27):9275-9278.
20. Vintonyak VV, Cala M, Lay F, Kunze B, Sasse F, Maier ME: Synthesis and biological evaluation of cruentaren A analogues. Chem Eur J (2008) 14:3709-3720.
21. Mukhopadhyay J, Das K, Ismail S, Koppstein D, Jang M, Hudson B, Sarafianos S, Tuske S, Patel J, Jansen R, Irschik H et al: The RNA polymerase "switch region" is a target of inhibitors. Cell (2008) 135:295-307. • The antibiotics myxopyronin, corallopyronin and ripostatin are demonstrated to target the bacterial RNA polymerase at the 'switch region', which is distant from binding sites of previously characterized RNA polymerase inhibitors.
22. Belogurov GA, Vassylyeva MN, Sevostyanova A, Appleman JR, Xiang AX, Lira R, Webber SE, Klyuyev S, Nudler E, Artsimovitch I, Vassylyev DG: Transcription inactivation through local refolding of the RNA polymerase structure. Nature (2008) 457(7227):332-335 • Structural studies of a myxopyronin derivative complexed with Thermus thermophilus RNAP holoenzyme lead to a plausible mechanism of action for this compound family.
23. Steinmetz H, Irschik H, Kunze B, Reichenbach H, Höfle G, Jansen R: Thuggacins, macrolide antibiotics active against Mycobacterium tuberculosis: Isolation from myxobacteria, structure elucidation, conformation analysis and biosynthesis. Chem Eur J (2007) 13:5822-5832.
24. Irschik H, Reichenbach H, Höfle G, Jansen R: The thuggacins, novel antibacterial macrolides from Sorangium cellulosum acting against selected Gram-positive bacteria. J Antibiot (2007) 60(12):733-738.
25. Bode HB, Wenzel SC, Irschik H, Höfle G, Müller R: Unusual biosynthesis of leupyrrins in the myxobacterium Sorangium cellulosum. Angew Chem Int Ed Engl (2004) 43(32):4163-4167.
26. Bode HB, Zeggel B, Silakowski B, Wenzel SC, Reichenbach H, Müller R: Steroid biosynthesis in prokaryotes: Identification of myxobacterial steroids and cloning of the first bacterial 2,3(S)-oxidosqualene cyclase from the myxobacterium Stigmatella aurantiaca. Mol Microbiol (2003) 47(2):471-481.
27. Gerth K, Steinmetz H, Höfle G, Jansen R: Chlorotonil A, a macrolide with a unique gem-dichloro-1,3-dione functionality from Sorangium cellulosum, So ce1525. Angew Chem Int Ed Engl (2008) 47(3):600-602.
28. Iizuka T, Fudou R, Jojima Y, Ogawa S, Yamanaka S, Inukai Y, Ojika M: Miuraenamides A and B, novel antimicrobial cyclic depsipeptides from a new slightly halophilic myxobacterium: Taxonomy, production, and biological properties. J Antibiot (2006) 59(7):385-391.
29. Jundt L, Steinmetz H, Luger P, Weber M, Kunze B, Reichenbach H, Höfle G: Isolation and structure elucidation of cruentarens A and B - novel members of the benzolactone class of ATPase inhibitors from the myxobacterium Byssovorax cruenta. Eur J Org Chem (2006) 2006(22):5036-5044.
30. Guo WJ, Tao WY: Phoxalone, a novel macrolide from Sorangium cellulosum: Structure identification and its anti-tumor bioactivity in vitro. Biotechnol Lett (2008) 30(2):349-356.
31. Kunze B, Bohlendorf B, Reichenbach H, Höfle G: Pedein A and B: Production, isolation, structure elucidation and biological properties of new antifungal cyclopeptides from Chondromyces pediculatus (myxobacteria). J Antibiot (Tokyo) (2008) 61(1):18-26.
32. Ahn JW, Jang KH, Chung SC, Oh KB, Shin J: Sorangiadenosine, a new sesquiterpene adenoside from the myxobacterium Sorangium cellulosum. Org Lett (2008) 10(6):1167-1169.
33. Li X, Yu TK, Kwak JH, Son BY, Seo Y, Zee OP, Ahn JW: Sorophinol C, a new free-radical scavenger from Sorangium cellulosum. J Microbiol Biotechnol (2008) 18(3):520-522.
34. Bock M, Buntin K, Müller R, Kirschning A: Stereochemical determination of thuggacins A-C, highly active antibiotics from the myxobacterium Sorangium cellulosum. Angew Chem Int Ed Engl (2008) 47(12):2308-2311.
35. Menche D, Arikan F, Perlova O, Horstmann N, Ahlbrecht W, Wenzel SC, Jansen R, Irschik H, Müller R: Stereochemical determination and complex biosynthetic assembly of etnangien, a highly potent RNA polymerase inhibitor from the myxobacterium Sorangium cellulosum. J Am Chem Soc (2008) 130:14234-14243. • Describes the identification of the biosynthetic machinery for the polyketide etnangien and the determination of its stereochemistry as guided by sequence analysis of the biosynthetic enzymes.
36. Janssen D, Albert D, Jansen R, Müller R, Kalesse M: Chivosazole A - elucidation of the absolute and relative configuration. Angew Chem Int Ed (2007) 46(26):4898-4901.
37. Bode HB, Müller R: The impact of bacterial genomics on natural product research. Angew Chem Int Ed (2005) 44(42):6828-6846. • Highlights current challenges in the field of natural product research and discusses approaches for the combination of genomic knowledge with applied biology and chemistry in order to identify, modify, or produce novel compounds.
38. Zhao JY, Zhong L, Shen MJ, Xia ZJ, Cheng QX, Sun X, Zhao GP, Li YZ, Qin ZJ: Discovery of an autonomously replicating plasmid pMF1 from Myxococcus fulvus and the development of a gene cloning system in Myxococcus xanthus. Appl Environ Microbiol (2008) 74:1980-1987. •• Identification of the first extra-chromosomal plasmid from myxobacteria. This discovery expands the toolbox for the genetic manipulation of these organisms and therefore has high impact for the myxobacterial research community.
39. Bode HB, Müller R: Analysis of myxobacterial secondary metabolism goes molecular. J Ind Microbiol Biotechnol (2006) 33(7):577-588.
40. Wenzel SC, Müller R: Myxobacterial natural product assembly lines: Fascinating examples of curious biochemistry. Nat Prod Rep (2007) 24(6):1211-1224. • Reviews the biosynthesis of myxobacterial secondary metabolites on the molecular level. Biosynthetic principles of the involved megasynthetases are discussed and biochemical curiosities are highlighted.
41. Staunton J, Weissman KJ: Polyketide biosynthesis: A millennium review. Nat Prod Rep (2001) 18(4):380-416.
42. Finking R, Marahiel MA: Biosynthesis of nonribosomal peptides. Annu Rev Microbiol (2004) 58:453-488.
43. Frank B, Wenzel SC, Bode HB, Scharfe M, Blöcker H, Müller R: From genetic diversity to metabolic unity: Studies on the biosynthesis of aurafurones and aurafuron-like structures in myxobacteria and streptomycetes. J Mol Biol (2007) 374(1):24-38.
44. Meiser P, Weissman KJ, Bode HB, Krug D, Dickschat JS, Sandmann A, Müller R: DKxanthene biosynthesis - understanding the basis for diversity-oriented synthesis in myxobacterial secondary metabolism. Chem Biol (2008) 15(8):771-781.
45. Buntin K, Rachid S, Scharfe M, Blöcker H, Weissman KJ, Müller R: Production of the highly antifungal isochromanone ajudazols in Chondromyces crocatus Cm c5: Biosynthetic machinery and cytochrome P450 tailoring modifications. Angew Chem Int Ed Engl (2008) 47(24):4595-4599.
46. Rachid S, Scharfe M, Blöcker H, Weissman KJ, Müller R: Unusual chemistry in the biosynthesis of the antibiotic chondrochlorens. Chem Biol (2009) 16(1)70-81.
47. Kopp M, Irschik H, Gross F, Perlova O, Sandmann A, Gerth K, Müller R: Critical variations of conjugational DNA transfer into secondary metabolite multiproducing Sorangium cellulosum strains So ce12 and So ce56: Development of a mariner-based transposon mutagenesis system. J Biotechnol (2004) 107(1):29-40.
48. Rachid S, Krug D, Kochems I, Kunze B, Scharfe M, Blöcker H, Zabriski M, Müller R: Molecular and biochemical studies of chondramide formation - highly cytotoxic natural products from Chondromyces crocatus Cm c5. Chem Biol (2006) 13(6):667-681.
49. Krug D, Müller R: Discovery of additional members of the tyrosine aminomutase enzme family and mutational analysis of CmdF. ChemBioChem (2009):DOI 10.1002/cbic.200800748.
50. Kopp M, Rupprath C, Irschik H, Bechthold A, Elling L, Müller R: SorF, a glycosyltransferase with promiscuous donor substrate specificity in vitro. ChemBioChem (2007) 8(7):813-819.
51. Li Y, Weissman KJ, Müller R: Myxochelin biosynthesis: Direct evidence for two- and four-electron reduction of a carrier protein-bound thioester. J Am Chem Soc (2008) 130:7554-7555.
52. Goldman BS, Nierman WC, Kaiser D, Slater SC, Durkin AS, Eisen J, Ronning CM, Barbazuk WB, Blanchard M, Field C, Halling C et al: Evolution of sensory complexity recorded in a myxobacterial genome. Proc Natl Acad Sci USA (2006) 103(41):15200-15205. • The complete sequence of the model strain Myxococcus xanthus DK1622 is reported, representing the first myxobacterial genome sequence. Theories about the evolutionary origins of the large bacterial chromosome (9.1 Mbp) are discussed.
53. Schneiker S, Perlova O, Kaiser O, Gerth K, Alici A, Altmeyer MO, Bartels D, Bekel T, Beyer S, Bode E, Bode HB et al: Complete genome sequence of the myxobacterium Sorangium cellulosum. Nat Biotechnol (2007) 25(11):1281-1289. •• The genome sequence of S cellulosum So ce56, containing the largest bacterial chromosome known to date (13.0 Mbp), is presented and compared to the M xanthus genome.
54. Ronning CM, Nierman WC: The genomes of Myxococcus xanthus and Stigmatella aurantiaca. In: Myxobacteria: Multicellularity and Differentiation. Whitworth D (Ed), ASM Press, Washington DC, USA (2007):285-298.
55. Thomas SH, Wagner RD, Arakaki AK, Skolnick J, Kirby JR, Shimkets LJ, Sanford RA, Loffler FE: The mosaic genome of Anaeromyxobacter dehalogenans strain 2CP-C suggests an aerobic common ancestor to the δ-proteobacteria. PLoS ONE (2008) 3(5):e2103.
56. Bode HB, Meiser P, Klefisch T, Cortina NS, Krug D, Göhring A, Schwär G, Mahmud T, Elnakady YA, Müller R: Mutasynthesis-derived myxalamids and origin of the isobutyryl-CoA starter unit of myxalamid B. ChemBioChem (2007) 8(17):2139-2144.
57. Meiser P, Bode HB, Müller R: The unique DKxanthene secondary metabolite family from the myxobacterium Myxococcus xanthus is required for developmental sporulation. Proc Natl Acad Sci USA (2006) 103(50):19128-19133.
58. Schley C, Altmeyer MO, Swart R, Müller R, Huber CG: Proteome analysis of Myxococcus xanthus by off-line two-dimensional chromatographic separation using monolithic poly-(styrene-divinylbenzene) columns combined with ion-trap tandem mass spectrometry. J Proteome Res (2006) 5(10):2760-2768. • The proteome of the model strain Myxococcus xanthus DK1622 is characterized, with a focus on the identification of high-molecular-weight polyketide synthases and non-ribosomal peptide synthetases. Intriguingly, this study shows that most of these megasynthetases are expressed under the tested experimental conditions.
59. Krug D, Zurek G, Revermann O, Vos M, Velicer GJ, Müller R: Discovering the hidden secondary metabolome of Myxococcus xanthus: A study of intraspecific diversity. Appl Environ Microbiol (2008) 74(10):3058-3068.
60. Krug D, Zurek G, Schneider B, Garcia R, Müller R: Efficient mining of myxobacterial metabolite profiles enabled by liquid-chromatography - electrospray ionization - time-of-flight mass spectrometry and compound-based principal component analysis. Anal Chim Acta (2008) 624:97-106. •• Modern mass spectrometry-coupled liquid chromatography techniques are combined with statistical analysis tools to analyze bacterial metabolite profiles. The developed method allows the efficient mining of secondary metabolomes for the presence of potentially novel natural products.
61. Gerth K, Müller R: Moderately thermophilic myxobacteria: Novel potential for production of natural products. Environ Microbiol (2005) 7(6):874-880.
62. Garcia RO, Reichenbach H, Ring MW, Müller R: Phaselicystaceae, fam. nov., Phaselicystis flava, gen. nov., sp. nov., an arachidonic acid-containing soil myxobacterium. Int J Syst Evol Microbiol (2009): in press.
63. Wenzel SC, Müller R: Recent developments towards the heterologous expression of complex bacterial natural product biosynthetic pathways. Curr Opin Biotechnol (2005) 16(6):594-606. • Discusses different approaches for the heterologous production of natural products with particular emphasis on polyketides and non-ribosomally biosynthesized peptide compounds.
64. Fu J, Wenzel SC, Perlova O, Gross F, Tang Z, Yin Y, Stewart AF, Müller R, Zhang Y: Efficient transfer of two large secondary metabolite pathways into heterologous hosts by transposition. Nucleic Acids Res (2008) 36(17):e113. •• A transposon-based approach for the delivery of large natural product biosynthetic pathways was established, as exemplified by the transfer of two myxobacterial biosynthetic gene clusters into different host organisms. In this study, the largest transposition yet reported for any system was achieved.
65. Yin J, Straight PD, Hrvatin S, Dorrestein PC, Bumpus SB, Jao C, Kelleher NL, Kolter R, Walsh CT: Genome-wide high-throughput mining of natural-product biosynthetic gene clusters by phage display. Chem Biol (2007) 14(3):303-312. • Describes a phage-display strategy for the rapid and unambiguous identification of genes encoding polyketide synthases and non-ribosomal peptide synthetases. This method may provide an efficient tool for the cloning of secondary metabolite gene clusters from individual bacterial genomes and multigenome environmental DNA.